Introduction
The branched chain amino acids isoleucine, valine, and leucine are essential nutrients for human growth and development (Adibi
1976). The enzymes methylmalonyl-CoA mutase, propionyl-CoA carboxylase, and isovaleryl-CoA dehydrogenase play pivotal roles in the metabolism of these amino acids. Deficiencies of these enzymes result in three classic organic acidemias, methylmalonic acidemia (MMA; OMIM #251000, #251100, #251110, #277400, #277410), propionic acidemia (PA; OMIM #606054), and isovaleric acidemia (IVA; OMIM #243500). MMA and PA are characterized by the potentially lethal accumulation of toxic metabolites, mainly 2-methylcitric acid, malonic acid, and propionyl-CoA (Kölker et al.
2003; Schwab et al.
2006).
The treatment mainly consists of protein reduction as well as avoidance of catabolism, and survival has greatly improved beyond childhood (Enns et al.
2007; Pena et al.
2012). However, the prognosis is still unsatisfactory with a high rate of severe long-term complications, such as renal failure, cardiac arrhythmias, cardiomyopathy, optic nerve atrophy with vision loss, pancreatitis, and mental retardation (Marquard et al.
2011; Sutton et al.
2012; Baumgartner et al.
2014; Fraser and Venditti
2016). The protein restricted diet may also cause complications, such as failure to thrive (van der Meer et al.
1996; Yannicelli et al.
2003). Mitochondrial dysfunction has been established in the pathophysiology of all long-term complications (Schwab et al.
2006; Chandler et al.
2009; de Keyzer et al.
2009; Fragaki et al.
2011; Melo et al.
2011; Wajner and Goodman
2011; Manoli et al.
2013; Baruteau et al.
2014; Wilnai et al.
2014; Zsengeller et al.
2014; Gallego-Villar et al.
2016; Erlich-Hadad et al.
2017). Occurrence of mental retardation is most likely multifactorial, for example cerebral damage during decompensations with metabolic encephalopathy (Kölker et al.
2006a, cerebral accumulation of toxic metabolites (Kölker et al.
2006b; Harting et al.
2008) and presumably mitochondrial dysfunction (Melo et al.
2011; Wajner and Goodman
2011) .
The demonstration of mitochondrial dysfunction is essential to improve the understanding of long-term complications and could be of major importance to develop and potentially evaluate (preventive) treatment strategies by identifying risk groups. The most reliable available evaluation of mitochondrial dysfunction is histological and biochemical assessment of a muscle biopsy. However, muscle biopsies are considered invasive and not acceptable for follow up of mitochondrial dysfunction over the years. Current plasma biomarkers, such as creatine kinase, lactate, pyruvate, alanine and proline levels, and the lactate to pyruvate ratio, have a low sensitivity and specificity (Mitochondrial Medicine Society's Committee on Diagnosis, Haas RH, Parikh et al.
2008; Davis et al.
2013,
2016). Serum fibroblast growth factor 21 (FGF-21) has been suggested as a biomarker for mitochondrial disease. Serum FGF-21 is stable with respect to processing and storage, has a higher specificity and sensitivity compared to other biomarkers, and is fast and inexpensive to determine (Suomalainen et al.
2011; Davis et al.
2013; Suomalainen
2013; Kim and Lee
2014; Ji et al.
2015; Lee
2015; Lehtonen et al.
2016; Montero et al.
2016). We studied the potential of serum FGF-21 measured in the stable metabolic period as a biomarker for long-term complications, attributed to mitochondrial failure, in patients with organic acidemias.
Discussion
This study demonstrates that FGF-21 can be a biomarker for long-term complications, attributed to mitochondrial dysfunction, in classic organic acidemia patients. Plasma FGF-21 levels were high in stable metabolic periods in patients with long-term complications, this was well before the onset of these complications. A median plasma FGF-21 level above 1500 pg/ml during a stable metabolic period, measured before the occurrence of long-term complications, had a positive predictive value of 0.83 on long-term complications, a negative predictive value of 1.00, and an odds ratio of 5.0. Plasma FGF-21 levels were not associated with growth, nutritional status or renal function.
Our results give additional proof to the hypothesis that mitochondrial dysfunction plays a role in long-term complications in classical organic acidemia patients (Wajner et al.
2004; Schwab et al.
2006; Chandler et al.
2009; de Keyzer et al.
2009; Fragaki et al.
2011; Melo et al.
2011; Wajner and Goodman
2011; Manoli et al.
2013; Baruteau et al.
2014; Gallego-Villar et al.
2014; Wilnai et al.
2014; Zsengeller et al.
2014; Gallego-Villar et al.
2016; Rivera-Barahona et al.
2017). Plasma FGF-21 levels were high in PA patients before they developed long-term complications, both before severe complications (such as lethal cardiomyopathy) and before milder complications (prolonged QT interval and slight left ventricular hypertrophy). Our observation of high plasma FGF-21 levels in a patient with QT prolongation, suggesting a role of mitochondrial dysfunction, is in line with Baumgartner et al. (
2007). In MMA, the renal complications and the high plasma FGF-21 levels could point toward a role of mitochondrial dysfunction in renal failure, which was also proposed by others (Manoli et al.
2013). Kölker et al have suggested that mitochondrial dysfunction is not caused by a direct toxicity of methylmalonic acid but by inhibition of the respiratory chain by 2-methylcitric acid, malonic acid, and propionyl-CoA, which are increased in MMA as well (Kölker et al.
2003). Furthermore, plasma FGF-21 levels can be elevated in chronic as well as acute kidney disease and an association between plasma FGF-21 levels and estimated glomerular filtration rate has been found in non OAD patients (Hindricks et al.
2014). In our patient population we did not observe an association between plasma FGF-21 levels and renal function plasma (creatinine levels). Furthermore, plasma FGF-21 levels were already elevated before the occurrence of kidney failure, nor was there an increase in plasma FGF-21 levels when renal function deteriorated.
In stable metabolic periods there is a clear difference in plasma FGF-21 levels in patients with long-term complications compared to those without. Importantly, in this patient cohort the majority of long-term complications occurred between 7 and 9 years of age. This suggests that by determination of plasma FGF-21 levels in the stable metabolic period in early childhood we can potentially identify risk groups for long-term complications. In the stable metabolic period, only one patient (case 11) had high plasma FGF-21 levels without long-term complications. This patient had his latest visit at the age of 4 years and based on our results and the occurrence of long-term complications mainly between 7 and 9 years of age, this patient can be identified as a potential risk patient for long-term complications. During decompensation, one patient (case 16) had a severe increase in plasma FGF-21 levels, which normalized thereafter. The high plasma FGF-21 levels in this case, could be due to either the decompensation itself or the increased rigorousness of protein restriction; the last was also reflected by the decreased plasma BCAA levels observed during this decompensation. Based on our results, we recommend measuring plasma FGF-21 levels in stable metabolic periods. A median plasma FGF-21 level above 1500 pg/ml measured during a stable metabolic period, before the occurrence of long-term complications, seems to predict long-term complications. The negative predictive value of 1.00 observed in this patient cohort should be interpreted with respect to the follow-up time and the fact that long-term complications can occur at later disease stage.
A total of three patients had died, one during the neonatal period (case 10), the others at the age of 8 (case 2) and 12 years (case 8) respectively. Case 8 had initially highly elevated plasma FGF-21 levels in stable conditions, which decreased over the years until the patient died due to lethal cardiomyopathy. This decrease in plasma FGF-21 plasma levels might be the consequence of the potentially lethal mitochondrial dysfunction.
In none of the MMA and PA patients, an association between plasma FGF-21 levels and nutritional status, with respect to protein intake and plasma levels of BCAA, alanine, phenylalanine, methionine, threonine, and proline, was found.
There are some potential limitations of this study. Firstly, a retrospective study design cannot make causal inferences and therefore a prospective study is required to confirm our observations. Secondly, this retrospective design could lead to a selection bias and the relatively small number of patients studied could lead to low internal validity.
This study provides a first insight into a potential biomarker for long-term complications in organic acidemias. Long-term complications occur despite good metabolic control (Ianchulev et al.
2003; de Keyzer et al.
2009). We suggest that mitochondrial dysfunction is an ongoing process independent of metabolic control. It is important to focus on the role of preventive treatment strategies. A potential preventive therapy is anti-oxidants administration. To date, the beneficial efficacy of anti-oxidant therapies varies, ranging from improvement of long-term complications to no beneficial effect (Baruteau et al.
2014; Gallego-Villar et al.
2014; Martinez Alvarez et al.
2016; Rivera-Barahona et al.
2017). Absence of therapy efficacy can be due to the relatively late initiation of anti-oxidants in disease progression. First, the results observed in this study, namely the association between plasma FGF-21 levels and the occurrence of long-term complications as well as the high positive and negative predictive value of a median plasma FGF-21 level above 1500 pg/ml, should be replicated in another cohort of classical organic acidemia patients. Other biomarkers for mitochondrial dysfunction, like growth differentiation factor 15 (GDF-15), should be included in order to identify their role and relation with the occurrence of long-term complications in these disorders and compare them to plasma FGF-21. Once the FGF-21 results are confirmed and the role of GDF-15 established, further research should determine if FGF-21 or other mitochondrial markers could play a role in the evaluation of preventive strategies concerning the consequences of mitochondrial impairment, and if FGF-21 plays a pathogenic role in the development of mitochondrial impairment.